Scan: Will the FDA approve a cure for Type 1 Diabetes before 2033?

← Back to scans

Will the FDA approve a cure for Type 1 Diabetes before 2033?

KXFDATYPE1DIABETES-33 · Health · 2026-05-07

19%

Agent

44%

Market Price

-25.0%

Edge

40%

Confidence

Volume: 8,350

Spread: 7.0c

Days to resolution: 2430

Markets in event: 1

Final Rationale

My independent forecast of 13.7% relied heavily on zimislecel's pivotal trial status and Fast Track designation, but the Devil's Advocate correctly identified math inconsistencies (the multiplicative chain actually yields ~19%) and that I underweighted portfolio effects from VX-264, Sernova, and CRISPR-based candidates I had no data on. I ACCEPT challenges 2, 4, and 5 (math/double-counting/portfolio), PARTIALLY ACCEPT challenge 1 (definitional 'cure' uncertainty cuts both ways), and REJECT challenge 3's relevance (sq4 was indeed noise but didn't drive the final number much). I'm moving up to ~19% to reflect the corrected chain math and broader pipeline. I deviate substantially from the 44% market because (a) there's NO reliability data on this market — no orderbook, volume, or liquidity confirmed; (b) zimislecel's pivotal readout to BLA timeline is genuinely tight for pre-2033 approval; and (c) the immunosuppression requirement creates real definitional risk for 'cure' resolution that retail markets may be glossing over.

Price vs. prediction

How the market moved after the agent's call. Solid blue line is the actual market price; dashed line is the agent's static forecast at $t{=}0$.

$n = 58$ follow-ups

Re-scan Context

This market has been scanned before. Previous predictions:

Date	Predicted	Market Price	Confidence
2026-04-30	19%	32%	45%
2026-04-21	18%	32%	50%

1. Planner Opus · Fermi decomposition + tool plan

Tools chosen: kalshi_data article_search web_search wikipedia_lookup code_execution

Sub-questions (Fermi decomposition)

Is there currently at least one Type 1 diabetes cure candidate in Phase 2 or Phase 3 clinical trials that could realistically complete trials and receive FDA review by 2033? (w=0.35)
Will at least one Type 1 diabetes cure candidate achieve Phase 3 trial success demonstrating insulin independence by 2031? (w=0.30)
Has the FDA shown willingness to use accelerated or breakthrough designation pathways that could fast-track a T1D cure approval within the 2026-2033 window? (w=0.20)
Is the current Kalshi prediction market pricing this event at above 25% probability? (w=0.15)

Planner reasoning

This question requires assessing the probability of an unprecedented medical breakthrough since no FDA-approved cure for Type 1 diabetes exists. The critical definitional issue is distinguishing a true cure (eliminating insulin dependence permanently without ongoing immunosuppression) from an improved treatment. Key reference classes: (1) Novel biologic/gene therapy approval timelines typically run 10-15 years from Phase 1 to approval; (2) Teplizumab for T1D delay took ~15 years from Phase 2 to 2022 approval; (3) CAR-T cell therapies took ~7 years. The most advanced candidates are Vertex VX-880 and VX-264 (encapsulated stem cell-derived islet cells), with Phase 1/2 data showing insulin independence in some patients. VX-264 specifically uses immunoprotective encapsulation to avoid immunosuppression, making it the most plausible path to a true cure label. For YES to occur: Phase 3 must initiate by 2027-2028, complete by 2030-2031, BLA filed 2031, FDA review completes by Jan 2033. This is tight but theoretically feasible with breakthrough designation and priority review. The temporal constraint is the binding factor - the science may be ready but the regulatory pipeline requires ~6-7 years minimum from current Phase 2 status. Multiple candidates in the pipeline (Vertex, CRISPR approaches, tolerance induction) improve odds via portfolio effect. Historical base rate for any single novel T1D therapeutic hitting approval in a given 7-year window from Phase 2 is approximately 5-15%, but the current pipeline is unusually mature compared to prior decades.

2. Research Parallel tool calls · legacy v2

Tool	Status	Time	Items
kalshi_data	OK	1.7s	-
article_search	OK	0.7s	-
web_search	OK	61.1s	-
wikipedia_lookup	OK	1.8s	-
code_execution	OK	0.0s	-

3. Evidence Synthesis Sonnet · 17 items · legacy v2

#	Strength	Credibility	Direction	Source	Claim	Priced In
1	STRONG	78	↑ UP	web_search	Zimislecel (formerly VX-880) is in an ongoing Phase 1/2/3 pivotal trial as of June 2025, with 10 participants no longer needing daily insulin after one year at full dose, and has received FDA Fast Track designation.	Yes
2	STRONG	80	↓ DOWN	web_search	Zimislecel requires ongoing immunosuppressive therapy, which under a strict 'cure' definition (eliminating both insulin dependence AND immunosuppression) may disqualify it from meeting the resolution criteria.	Yes
3	STRONG	90	↓ DOWN	web_search	Tzield (teplizumab) is only FDA-approved for delaying progression to Stage 3 T1D, not curing it; it does not eliminate insulin dependence and thus does not represent a cure candidate.	Yes
4	STRONG	85	↓ DOWN	wikipedia_lookup	Drug development from Phase 1 to FDA approval typically takes more than a decade, establishing a challenging baseline for any candidate currently in Phase 1/2 trials to achieve approval by 2033.	Yes
5	MODERATE	45	NEUTRAL	code_execution	A quantitative model combining pipeline candidates and historical approval rates estimates a ~17% probability that at least one of three T1D cure candidates succeeds, but only ~5.8% as a final combined estimate accounting for timeline constraints.	No
6	STRONG	88	↓ DOWN	wikipedia_lookup	As of 2024, the only FDA-approved stem cell therapy is hematopoietic stem cell transplantation; no stem cell-derived islet or other T1D cure therapy has been approved, confirming no existing approval precedent for this class.	Yes
7	MODERATE	72	↑ UP	web_search	Zimislecel Phase 1/2/3 pivotal trial is progressing as planned as of June 2025, with strong early efficacy data (10/10 full-dose patients insulin-independent at 1 year), supporting plausibility of Phase 3 success before 2031.	Yes
8	MODERATE	75	↓ DOWN	web_search	The zimislecel trial sample size is very small (10 full-dose participants at 1-year follow-up as of June 2025), and Phase 3 pivotal trials typically require hundreds of patients with multi-year follow-up, making a 2031 completion timeline highly uncertain.	Yes
9	MODERATE	72	↓ DOWN	article_search	FDA has recently rejected or discouraged at least 8 experimental drugs in the past year (as of March 2026), citing insufficient evidence, signaling a potentially tougher approval environment for novel biologics and cell therapies.	Yes
10	WEAK	55	↑ UP	article_search	Vertex Pharmaceuticals demonstrated Phase 3 success for its kidney drug povetacicept in March 2026, indicating Vertex has regulatory execution capability, though this is in a different indication than T1D.	Yes
11	WEAK	55	↓ DOWN	article_search	Gene therapy trials have recently encountered safety deaths and setbacks (e.g., two boys died in a Duchenne muscular dystrophy gene therapy trial), reflecting general risk of novel advanced therapies that could parallel T1D cell therapy risks.	Yes
12	STRONG	80	↑ UP	web_search	Zimislecel (VX-880) has been granted FDA Fast Track designation, confirming the FDA has already shown willingness to use expedited pathways for T1D cell therapies.	Yes
13	MODERATE	70	↑ UP	article_search	The FDA Commissioner's National Priority Voucher (CNPV) program, launched recently, is issuing fast-track review vouchers to companies studying novel therapies (e.g., psychedelics), indicating a broader institutional willingness to use expedited review mechanisms.	No
14	MODERATE	68	↓ DOWN	article_search	Under the current FDA leadership (post-November 2025 top drug regulator resignation, Kennedy-led HHS), the agency has shown increased willingness to reject drugs lacking robust evidence, creating regulatory uncertainty for novel cell therapies.	Yes
15	MODERATE	72	↓ DOWN	article_search	FDA rejected or discouraged at least 8 experimental drugs (March 2026 report), including gene therapies, suggesting the current FDA may apply stricter evidentiary standards even for rare/serious diseases.	Yes
16	MODERATE	75	↑ UP	web_search	Tzield received FDA acceptance into the National Priority Voucher program for accelerated review of an expanded pediatric indication, confirming FDA uses multiple fast-track mechanisms for T1D-related therapies.	Yes
17	WEAK	20	NEUTRAL	article_search	No Kalshi market data for this specific question was found in any of the research sources; market pricing for this question is unknown.	No

Information Gaps

No data on Kalshi or other prediction market pricing for this specific question (sq4 entirely unaddressed by research)
No specific information on VX-264 (encapsulated islet cell therapy without immunosuppression) current trial status or timeline — this is the most plausible 'true cure' candidate
No data on CRISPR-based T1D cure approaches currently in human trials (e.g., Sigilon, Practical Immunity, or other tolerance-induction approaches)
No information on whether Vertex has filed for or received Breakthrough Therapy Designation (not just Fast Track) for zimislecel
No data on the planned Phase 3 enrollment size and estimated completion date for zimislecel's pivotal trial
No information on BNT111 or other immune tolerance approaches that might achieve insulin independence without ongoing immunosuppression
Limited information on long-term durability of zimislecel's insulin independence (beyond 1-year follow-up)
No data on regulatory definition of 'cure' vs. 'treatment' that the FDA would use to resolve the question — particularly whether requiring immunosuppression disqualifies a candidate
No information on FDA/Vertex pre-BLA meetings or rolling review agreements that could accelerate timeline

Key Uncertainties

Definitional ambiguity: Whether the question resolves YES if immunosuppression is required (zimislecel requires it) or only if a truly drug-free cure is achieved (VX-264 encapsulation approach)
VX-264 trial status and timeline: If VX-264 (immunosuppression-free encapsulated islet cells) achieves comparable efficacy, it represents the clearest path to 'cure' resolution — but its current phase is unknown from this data
FDA leadership instability under Kennedy/HHS: Whether current regulatory environment becomes more or less favorable for novel cell/gene therapies over the 2026-2033 window
Clinical trial enrollment pace: Whether zimislecel and other candidates can complete Phase 3 enrollment and follow-up within the required timeline for a 2033 approval
Safety signals: Whether long-term follow-up reveals unexpected adverse events (e.g., tumor formation from stem cell-derived islets) that halt trials
Whether Vertex pursues accelerated approval based on surrogate endpoints (C-peptide/insulin independence) rather than waiting for full long-term outcomes data
Portfolio effect: How many additional candidates enter Phase 2/3 between now and 2028, improving overall probability

Market Context

Price: None · 7d: None · 30d: None
Volume: UNKNOWN · Depth: UNKNOWN
Reliability: NO DATA — No Kalshi or prediction market data was found for this specific question in any research source

4. Independent Forecaster Opus · No market price · legacy v2 Did NOT see market price

Independent estimate: 14% (48% confidence)

base rate

13%

50% conf

evidence driven

16%

45% conf

contrarian

12%

50% conf

Spread

4pp

Low disagreement

sq1: Is there currently at least one Type 1 diabetes cure candidate in Phase 2 or Phase 3 clinical trials that could realistically complete trials and receive FDA review by 2033?

75%

Zimislecel is in Phase 1/2/3 pivotal trial with Fast Track designation and strong early efficacy data (10/10 insulin-independent). The question asks if a candidate exists that COULD realistically complete and receive review — not whether it will succeed. With ~7 years remaining and an active pivotal trial, this is plausible but tight. However, the 'cure' definitional issue looms — zimislecel requires immunosuppression. If we interpret broadly (any candidate that could plausibly be reviewed), ~75%. Base rate for a Phase 1/2 candidate reaching FDA review in 7 years is ~25-35%, but pivotal trial status raises this.

sq2: Will at least one Type 1 diabetes cure candidate achieve Phase 3 trial success demonstrating insulin independence by 2031?

32%

Base rate for Phase 3 success in novel cell therapies is ~50-60% conditional on reaching Phase 3, but timeline to 2031 is the binding constraint. Zimislecel pivotal data may read out 2028-2030 with possible insulin independence demonstration. Small sample sizes, long follow-up needed, recent FDA stricter posture, and gene therapy safety setbacks pull this down. ~32% reflects meaningful chance Vertex hits primary endpoint on time but real execution risk.

sq3: Has the FDA shown willingness to use accelerated or breakthrough designation pathways that could fast-track a T1D cure approval within the 2026-2033 window?

78%

Fast Track for zimislecel is confirmed. CNPV program exists. Tzield got priority voucher. FDA has clear track record of expedited pathways for T1D. Counter: Kennedy/HHS leadership creating uncertainty and stricter evidentiary bar. Net: high probability FDA WILL use expedited pathways if data supports it (~78%). This sub-question is about willingness, not outcome.

sq4: Is the current Kalshi prediction market pricing this event at above 25% probability?

55%

No direct evidence, but prior market scans showed 32% pricing on this question on Polymarket-style markets. Kalshi may price similarly given same underlying question. Slight lean toward YES given prior 32% observations, but Kalshi may not even have this market or could price differently. ~55%.

Show full reasoning trace

base rate: Base rate for an unprecedented FDA-approved 'cure' for an autoimmune disease in any 7-year window is very low (<5%). However, zimislecel's pivotal trial status and strong early data raise this materially. Historical timeline from pivotal trial start to BLA approval for breakthrough biologics is 5-8 years.

evidence updates: Zimislecel pivotal trial + Fast Track + strong early efficacy: pushes UP from ~5% base to ~15%. Requirement for immunosuppression and FDA 'cure' labeling reluctance: pushes DOWN ~3-5%. Multiple candidates in pipeline (portfolio effect): pushes UP ~2%. Kennedy FDA stricter posture: pushes DOWN ~2%. Net: ~12-15%.

combination method: I rejected the naive weighted average because the sub-questions measure preconditions, not the conjunctive event. Instead used a multiplicative chain of necessary conditions, then sanity-checked against base rates.

final: Final estimate ~13%. Strong candidate exists but timeline is very tight, definitional 'cure' framing is a meaningful obstacle (zimislecel needs immunosuppression), and FDA execution risk is real. Aligned with prior forecast trajectory of 18-19% but slightly lower given continued tight timeline and Kennedy FDA risk.

ensemble: {'ensemble_count': 3, 'perspectives': {'base_rate': {'p_yes': 0.13, 'confidence': 0.5}, 'evidence_driven': {'p_yes': 0.16, 'confidence': 0.45}, 'contrarian': {'p_yes': 0.12, 'confidence': 0.5}}, 'spread': 0.04, 'individual_p_yes': {'base_rate': 0.13, 'evidence_driven': 0.16, 'contrarian': 0.12}}

5. Devil's Advocate Sonnet · legacy v2 Market price revealed

Math Error Missing Info Reasoning Flaw

Challenges

The 'cure' definitional question is treated as a major downward factor, but the forecaster never resolves how THIS market will adjudicate it. If the resolution criteria treat FDA approval of zimislecel (even with immunosuppression) as a 'cure', the immunosuppression objection collapses. Without knowing the resolution source, applying a -3 to -5% downward adjustment for definitional strictness is somewhat arbitrary — it could equally be neutral or even mildly positive if the market resolves liberally.
Sub-question decomposition is muddled: sq1 asks if a candidate COULD be reviewed (75%), sq2 asks Phase 3 success by 2031 (32%), sq3 asks FDA willingness for fast-track (78%). The forecaster says they used a 'multiplicative chain' but 0.75 × 0.32 × 0.78 ≈ 0.187, while the final answer is 0.137. The actual combination method is opaque and the math doesn't transparently support the final number.
sq4 (about market pricing) is included as a sub-question but is irrelevant to the actual probability of FDA approval — it shouldn't factor into the conjunctive chain at all. Including it suggests confusion about what the sub-questions are decomposing.
The forecaster anchors heavily on a quantitative model estimate of ~17% (cited as MODERATE evidence) but ends up below it at 13.7%, with the downward push driven largely by Kennedy FDA risk and 'tight timeline' — both of which may already be priced into the 17% base model. Possible double-counting of negative factors.
The pipeline portfolio effect gets only +2%, but there are multiple candidates (zimislecel, VX-264, Sernova, CRISPR/encapsulated approaches) — and the forecaster admits in info gaps they have NO data on most of them. Wider uncertainty from missing pipeline info should push the estimate UP (more shots on goal) or at least widen the confidence interval, not be treated as ~neutral.
Confidence of 0.483 with multiple acknowledged information gaps (no data on VX-264, CRISPR approaches, BTD status, Phase 3 timeline specifics) seems too high. The forecast should be more humble given how much pipeline information is missing.

Suggested adjustment: +5pp

Modest upward adjustment warranted for two reasoning flaws: (1) the multiplicative chain math actually yields ~0.19, not 0.137, suggesting unjustified additional downward adjustments; (2) missing information on multiple pipeline candidates (VX-264, CRISPR, encapsulated cell approaches) should add portfolio probability rather than being ignored. Not adjusting toward the 44% market because there's no liquidity/orderbook data and the divergence may reflect market noise or different resolution criteria interpretation.

Market comparison: Forecaster: 13.7%, Market: 44% (reliability: NO DATA). The 30-point divergence is striking but the market price has no reliability backing — no volume, no orderbook, no trend data. The market may be pricing a more liberal 'cure' definition or reflecting hype around zimislecel. Without confirming market liquidity and resolution criteria, the divergence shouldn't drive a large adjustment, but the forecaster's own math errors and missing pipeline data justify a small upward move.

6. Aggregator Opus · final calibrated forecast

19% (40% confidence)